Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COPCOV: Chloroquine/Hydroxychloroquine for COVID-19 Prevention
NCT04303507Completed
- Sponsor
- University of Oxford
- Start
- Apr 2020
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Chloroquine or Hydroxychloroquine with Placebo (2 arms). Primary endpoint: Number of symptomatic COVID-19 infections at 90 days. Started Apr 2020; status: completed.
02
Drugs
chloroquinehydroxychloroquine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04303507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04303507.